Suppr超能文献

法国心脏病学会心脏节律与刺激小组以及法国老年医学与老年病学学会关于老年起搏器和植入式心脏除颤器患者管理的立场文件

Position paper for management of elderly patients with pacemakers and implantable cardiac defibrillators Groupe de rythmologie et stimulation cardiaque de la Société française de cardiologie et Société française de gériatrie et gérontologie.

作者信息

Fauchier Laurent, Alonso Christine, Anselme Frédéric, Blangy Hugues, Bordachar Pierre, Boveda Serge, Clementy Nicolas, Defaye Pascal, Deharo Jean-Claude, Friocourt Patrick, Gras Daniel, Halimi Franck, Klug Didier, Mansourati Jacques, Obadia Benjamin, Pasquié Jean-Luc, Pavin Dominique, Sadoul Nicolas, Taieb Jérôme, Piot Olivier, Hanon Olivier

机构信息

CHU Trousseau et Université François Rabelais, Tours, France.

Clinique Ambroise Paré, Neuilly-sur-Seine, France.

出版信息

Geriatr Psychol Neuropsychiatr Vieil. 2016 Sep 1;14(3):239-64. doi: 10.1684/pnv.2016.0628.

Abstract

Despite the increasingly high rate of implantation of pacemakers (PM) and cardioverter-defibrillators (ICD) in elderly patients, data supporting their clinical and cost-effectiveness in this age stratum are ambiguous and contradictory. We reviewed the data regarding the applicability, safety, and effectiveness of the conventional pacing, ICD and cardiac resynchronization therapy (CRT) in elderly patients. Although peri-procedural risk may be slightly higher in the elderly, the procedure of implantation of PMs and ICDs is still relatively safe in this age group. In older patients with sinus node disease, a general consensus is that dual chamber pacing, along with the programming of an algorithm to minimise ventricular pacing is preferred. In very old patients presenting with intermittent or suspected AV block, VVI pacing may be appropriate. In terms of correcting potentially life-threatening arrhythmias, the effectiveness of ICD therapy is comparable in older and younger individuals. However, the assumption of persistent ICD benefit in the elderly population is questionable, as any advantage of the device on arrhythmic death may be attenuated by a higher total non-arrhythmic mortality. While septuagenarians and octogenarians have higher annual all-cause mortality rates, ICD therapy may remain effective in selected patients at high risk of arrhythmic death and with minimum comorbidities despite advanced age. ICD implantation among the elderly, as a group, may not be cost-effective, but the procedure may reach cost-effectiveness in those expected to live >5-7 years after implantation. The elderly patients usually experience a significant functional improvement after CRT, similar to that observed in middle-aged patients. Management of CRT non responders remains globally the same, while considering a less aggressive approach in terms of re interventions (revision of LV lead placement, addition of a RV or LV lead, LV endocardial pacing configuration). Overall, age, comorbidities and comprehensive geriatric assessment should be the decisive factor in making a decision on device implantation selection for survival and well-being benefit in elderly patients.

摘要

尽管老年患者植入起搏器(PM)和心脏复律除颤器(ICD)的比例越来越高,但支持其在该年龄层的临床疗效和成本效益的数据却模糊且相互矛盾。我们回顾了有关传统起搏、ICD和心脏再同步治疗(CRT)在老年患者中的适用性、安全性和有效性的数据。尽管老年患者围手术期风险可能略高,但PM和ICD植入手术在该年龄组中仍相对安全。对于老年窦房结疾病患者,普遍的共识是双腔起搏以及将心室起搏最小化的算法编程是首选。对于出现间歇性或疑似房室传导阻滞的高龄患者,VVI起搏可能是合适的。在纠正潜在的危及生命的心律失常方面,ICD治疗在老年和年轻个体中的有效性相当。然而,认为ICD对老年人群有持续益处的假设值得怀疑,因为该设备在心律失常死亡方面的任何优势可能会被更高的非心律失常总死亡率所削弱。虽然七旬和八旬老人的年度全因死亡率较高,但ICD治疗在某些尽管年龄较大但心律失常死亡风险高且合并症最少的患者中可能仍然有效。作为一个群体,老年患者植入ICD可能不具有成本效益,但在那些预计植入后能存活>5 - 7年的患者中,该手术可能具有成本效益。老年患者通常在CRT后功能有显著改善,类似于中年患者。CRT无反应者的管理总体上保持不变,同时在再干预方面(左心室导线位置的修正、增加右心室或左心室导线、左心内膜起搏配置)考虑采取不太积极的方法。总体而言,年龄、合并症和全面的老年评估应是决定为老年患者选择植入设备以获得生存和健康益处的决定性因素。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验